Getinge B stock holds steady as 2025 sales reached SEK 33.9 billion

Getinge B stock stays anchored by SEK 33.9 billion in 2025 net sales and an adjusted EBITA margin of 16.5%, with Q4 2025 sales at SEK 8.7 billion and net income at SEK 2.0 billion.

Getinge B (SE0000202624) is supported by a 2025 financial base of SEK 33.9 billion in net sales, an adjusted EBITA margin of 16.5%, and net income of SEK 2.0 billion, all disclosed in the companys latest annual report. The same report showed Q4 2025 net sales of SEK 8.7 billion and Q4 2025 organic growth of 4.5%, giving the stock a clear earnings reference point even without a fresh event in the available search results.

SEK 33.9 billion sets the frame

Getinge reported full-year 2025 net sales of SEK 33.9 billion, up 4.1% from SEK 32.6 billion in 2024, while adjusted EBITA rose to SEK 5.6 billion from SEK 5.0 billion a year earlier. The company also lifted its adjusted EBITA margin to 16.5% in 2025 from 15.3% in 2024, a quantified improvement that matters more to investors than broad sector language.

Q4 2025 added another data point: sales reached SEK 8.7 billion and organic growth was 4.5%, according to the annual report. Net income for the quarter came in at SEK 2.0 billion, which keeps the profit line central when the market looks at the stock through margin and earnings quality.

Margin matters most

The 2025 numbers show why Getinge B stock is judged on profitability, not only revenue. Adjusted EBITA increased by SEK 0.6 billion year over year, and the margin gain of 1.2 percentage points gave the business more room to absorb cost pressure in the operating model.

That framework also matters because the annual report ties the 2025 result to a larger base of SEK 33.9 billion in sales. For a medtech group, the combination of sales growth and a 16.5% adjusted EBITA margin is the kind of evidence investors can measure against future quarters.

Q4 2025 kept growth positive

Q4 2025 revenue of SEK 8.7 billion and organic growth of 4.5% show that the year ended with momentum rather than a flat finish. The market can compare that quarter directly with the full-year sales base of SEK 33.9 billion and the margin expansion to 16.5%.

Net income of SEK 2.0 billion in Q4 2025 also gave the period a strong bottom-line anchor. That figure is especially relevant because it sits alongside the full-year adjusted EBITA of SEK 5.6 billion, linking quarterly execution to annual profitability.

What the product mix means

Getinge sells equipment and systems across acute care, life science, and surgical workflows, and those segments feed the sales and margin numbers that matter most in the stock. The 2025 report shows that the companys business is still being judged by whether it can translate that mix into stable organic growth and a rising adjusted EBITA margin.

For investors, the practical takeaway is simple: the 2025 report gives Getinge B stock three hard reference points - SEK 33.9 billion in sales, SEK 5.6 billion in adjusted EBITA, and a 16.5% margin - against which future quarters will be measured.

Latest share context

With no dated price available in the search results, the valuation discussion in this article is anchored to the companys 2025 report rather than a live quote. The stock case therefore rests on the reported figures: SEK 33.9 billion in net sales, SEK 5.6 billion in adjusted EBITA, and SEK 2.0 billion in Q4 2025 net income.

Getinge B stock facts

• Company: Getinge AB (publ)
• ISIN: SE0000202624
• Ticker: XETRA: GTT
• Trading venue: Nasdaq Stockholm
• Sector / Industry: Health Care Equipment & Supplies
• Index membership: OMXS30
• Market capitalization: not included in the available search results